US2021290735A1PendingUtilityA1

Tissue matrix materials and enzymatic adhesives

63
Assignee: LIFECELL CORPPriority: Jan 30, 2017Filed: Feb 2, 2021Published: Sep 23, 2021
Est. expiryJan 30, 2037(~10.6 yrs left)· nominal 20-yr term from priority
A01N 1/128A01N 1/126A61L 2430/40A61L 27/3695A61L 27/3687A61L 27/367A61L 27/3625A61L 27/3604A61L 27/34A61L 27/24A61L 24/102A61K 35/18A61K 38/39A61K 48/00C12N 9/1048A01N 1/0226A01N 1/0231
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application relates to use of transglutaminases to treat various tissue matrix products. The methods can include application of a transglutaminase to a partially denatured collagen-containing tissue matrix and implantation of the tissue matrix. The transglutaminase can facilitate adhesion with another collagen-containing tissue matrix, tissue surrounding the tissue matrix after implantation, or both.

Claims

exact text as granted — not AI-modified
1 . A tissue treatment product, comprising:
 an acellular tissue matrix having a substantially intact acellular collagen tissue matrix portion, and a surface region comprising partially denatured collagen, wherein the partially denatured collagen comprises collagen matrix formed from the same tissue as the substantially intact acellular collagen tissue matrix portion such that the partially denatured collagen is formed from the native collagen framework of the intact tissue matrix and is connected to the intact tissue matrix.   
     
     
         2 . The product of  claim 1 , wherein the acellular tissue matrix comprises sponge formed from particulate. 
     
     
         3 . The product of  claim 1 , wherein the acellular tissue matrix is in the form of a sheet. 
     
     
         4 . The product of  claim 1 , wherein the acellular tissue matrix is produced from tissue derived from a tissue selected from skin, fascia, adipose, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, muscle, and intestinal tissue. 
     
     
         5 . The product of  claim 1 , wherein the acellular tissue matrix is produced from tissue derived from muscle. 
     
     
         6 . The product of  claim 1 , wherein the acellular tissue matrix comprises muscle tissue matrix. 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . A tissue treatment product, comprising:
 a first acellular tissue matrix having a substantially intact acellular collagen tissue matrix, and a surface region comprising partially denatured collagen; and   a second acellular tissue matrix having a substantially intact acellular collagen tissue matrix, and a surface region comprising partially denatured collagen, the second acellular tissue matrix joined to the surface region of the first acellular tissue matrix.   
     
     
         10 . The product of  claim 9 , wherein the surface region of the first acellular tissue matrix and the surface region of the second acellular tissue matrix comprise transglutaminase. 
     
     
         11 . The product of  claim 10 , wherein the first acellular tissue matrix and second acellular tissue matrix are joined to one another by bonds formed between gamma-carboxamide groups of glutamine residues with primary amino acids, the bonds catalyzed by the transglutaminase. 
     
     
         12 . The product of  claim 9 , wherein the first acellular tissue matrix and the second acellular tissue matrix are contacted with one another to produce a multi-layer sheet. 
     
     
         13 . The product of  claim 9 , wherein the first acellular tissue matrix and the second acellular tissue matrix comprise sponge formed from particulate. 
     
     
         14 . The product of  claim 9 , sheet wherein the first acellular tissue matrix and the second acellular tissue matrix are each in the form of a sheet. 
     
     
         15 . The product of  claim 9 , wherein the first acellular tissue matrix and the second acellular tissue matrix are produced from tissue derived from a tissue selected from skin, fascia, adipose, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, muscle, and intestinal tissue. 
     
     
         16 . The product of  claim 9 , wherein the first acellular tissue matrix and the second acellular tissue matrix are produced from tissue derived from muscle. 
     
     
         17 . The product of  claim 9 , wherein the first acellular tissue matrix and the second acellular tissue matrix comprise muscle matrix.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.